|
|
|
|
|
|
Sponsors and Collaborators: |
Masonic Cancer Center, University of Minnesota National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00258427 |
RATIONALE: A peripheral stem cell, bone marrow, or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for Fanconi's anemia.
PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating patients who are undergoing a donor stem cell transplant for Fanconi's anemia.
Condition | Intervention |
Fanconi Anemia Graft Versus Host Disease |
Drug: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: filgrastim Drug: fludarabine phosphate Drug: methylprednisolone Drug: mycophenolate mofetil Procedure: allogeneic bone marrow transplantation Procedure: graft-versus-tumor induction therapy Procedure: peripheral blood stem cell transplantation Procedure: umbilical cord blood transplantation |
MedlinePlus related topics: | Anemia Bone Marrow Transplantation Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02 |
Estimated Enrollment: | 25 |
Study Start Date: | March 2002 |
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients are stratified according to donor/recipient HLA type (identical vs other).
After completion of study treatment, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Ages Eligible for Study: | up to 44 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of high-risk Fanconi's anemia, as defined by ≥ 1 of the following:
Advanced myelodysplastic syndromes (MDS)
Has a related or unrelated donor available that meets 1 of the following criteria:
PATIENT CHARACTERISTICS:
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY: Not specified
United States, Minnesota | |||||
Masonic Cancer Center at University of Minnesota | Recruiting | ||||
Minneapolis, Minnesota, United States, 55455 | |||||
Contact: Clinical Trials Office - Masonic Cancer Center at University o 612-624-2620 |
Masonic Cancer Center, University of Minnesota |
National Cancer Institute (NCI) |
Study Chair: | Margaret L. MacMillan, MD | Masonic Cancer Center, University of Minnesota |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000450841, UMN-2002LS014, UMN-MT2002-02 |
First Received: | November 22, 2005 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00258427 |
Health Authority: | Unspecified |
|
|
|
|
|